Oral administration of bruton’s tyrosine kinase inhibitors impairs GPVI-mediated platelet function

Medicine & Life Sciences

• platelet membrane glycoprotein VI 100%
• Agammaglobulinaemia Tyrosine Kinase 85%
• Oral Administration 50%
• PCI 32765 34%
• Platelet Activation 25%
• Platelet Aggregation 17%
• Psychological Inhibition 14%
• Hemorrhage 11%
• In Vitro Techniques 10%
• Tec protein-tyrosine kinase 9%
• Immunoreceptor Tyrosine-Based Activation Motif 9%
• Bruton type agammaglobulinemia 8%
• Mantle-Cell Lymphoma 7%
• Phospholipases 7%
• P-Selectin 7%
• B-Cell Chronic Lymphocytic Leukemia 6%
• United States Food and Drug Administration 5%
• Fibrinogen 5%
• Glycoproteins 4%
• Signal Transduction 4%
• Blood Platelets 4%
• B-Lymphocytes 4%
• Phosphorylation 4%
• Mutation 3%
• Proteins 2%
• Therapeutics 1%